In this online, self-learning activity:
Adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) is a rare genetic disorder caused by mutations in the adenosine deaminase (ADA) gene. ADA-SCID is a specific form of severe combined immunodeficiency that results from ADA deficiency. Mutations in the ADA gene result in an accumulation of deoxyadenosine which leads to the destruction of lymphocytes, affecting the integrity of the immune system. This disease leaves individuals highly susceptible to infection such as pneumonia, chronic diarrhea, and oral thrush, which typically manifests soon after birth. The median age at diagnosis is between 1-3 months of age, although there is variability with some individuals having a later presentation onset. ADA deficiency accounts for approximately 10-15% of all SCID cases with an overall prevalence of 1 in 500,000 live births. It remains a rare disease and requires specialized immunologists, novel gene therapies, and transplant physicians to create a wholistic care plan.
HCPs including but not limited to: pediatric immunologists and pediatric infectious disease experts; physician associates, nurse practitioners, and nurses who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who clinically encounter pediatric patients with inherited metabolic and immune disorders.
Commercial Support Disclosure: This program is supported by an educational grant from Cheisi.
This activity is free of charge.
Release Date: February 01, 2025 -- Expiration Date: February 01, 2027
Faculty: Eyal Grunebaum, MD
Faculty introduction and disclosures |
Introductory content · SCID & ADA-SCID Epidemiology · Overview of primary immunodeficiencies and SCID · ADA-SCID disease characteristics, pathophysiology, clinical presentation, complications · Diagnostic methods |
NBS · Preliminary adoption · Benefits, impact on healthcare costs and patient survival General approach to treating SCID Treatment of ADA-SCID · Biomarkers and clinical monitoring · HSCT · ERT · Gene therapy · Long-term outcomes Patient case(s) |
Summary, conclusions, and best practice recap |
By the end of the session the participant will be able to:
ACCME Activity # 202909088
ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ABP MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
ABP MOC Credit Type: Lifelong Learning and Self-Assessment
Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABP.
Pharmacists: This activity is not approved for continuing pharmacy education credit.
Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.
Physician Associates: The American Academy of Physician Associates (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosures of Faculty: Eyal Grunebaum, MD, Professor in Pediatrics and Immunology, University of Toronto, has received financial compensation from Chiesi for speaker’s bureau work and consulting (relationship has ended).
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL discuss off-label uses of a commercial product.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Cheisi.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
On the road to eliminating pneumococcal diseases: a focus on vaccination practice in adults
The present and future state of care in hereditary angioedema (HAE)